Drug Patents owned by Seagen

1. Drug name - TUKYSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7452895 SEAGEN Quinazoline analogs as receptor tyrosine kinase inhibitors
Nov, 2024

(2 years from now)

US8648087 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Apr, 2031

(8 years from now)

CN101356171A SEAGEN N4-Phenyl-Quinazoline-4-Amine Derivatives And Related Compounds As Erbbi Type Receptor Tyrosine Kinase Inhibitors For The Treatment Of Hyperproliferative Diseases
Jun, 2016

(6 years ago)

CN102432552B SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

CN103772373B SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

CN103664802A SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

CN102432552A SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

CN103772373A SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

CN103664802B SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

CN102887891B SEAGEN N4-Phenyl-Quinazoline - -4 - Amine Derivatives And Related Compounds
Nov, 2026

(4 years from now)

CN102887891A SEAGEN N4-Phenyl - -4 - Amine Derivatives And Related Compounds
Nov, 2026

(4 years from now)

IN200600688P1 SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

IN245128B SEAGEN A Substituted Quinazoline Compound Including Resolved Enantiomers, Diastereomers, And Pharmaceutically Acceptable Salts Thereof
Aug, 2024

(1 year, 10 months from now)

IN200804058P1 SEAGEN Erbb Inhibitors
Nov, 2026

(4 years from now)

IN304285B SEAGEN Erbb Inhibitors
Nov, 2026

(4 years from now)

EP1660090B1 SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

EP1660090A4 SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

EP1660090A1 SEAGEN Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
Aug, 2024

(1 year, 10 months from now)

EP2090575B1 SEAGEN Processes And Intermediates For The Preparation Of N4-Phenyl-Quinazoline-4-Amine Derivatives
Nov, 2026

(4 years from now)

EP2090575A1 SEAGEN Processes And Intermediates For The Preparation Of N4-Phenyl-Quinazoline-4-Amine Derivatives
Nov, 2026

(4 years from now)

EP1971601A2 SEAGEN N4-Phenyl-Quinazoline-4 -Amine Derivatives And Related Compounds As Erbb Type I Receptor Tyrosine Kinase Inhibitors For The Treatment Of Hyperproliferative Diseases
Nov, 2026

(4 years from now)

EP1971601B1 SEAGEN N4-Phenyl-Quinazoline-4 -Amine Derivatives And Related Compounds As Erbb Type I Receptor Tyrosine Kinase Inhibitors For The Treatment Of Hyperproliferative Diseases
Nov, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693989 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases May, 2027

(4 years from now)

US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor Oct, 2032

(10 years from now)

Drugs and Companies using TUCATINIB ingredient

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.